Tesamorelin (Egrifta): The FDA-Approved GHRH Analogue — Mechanism, Benefits & Clinical Overview

What is Tesamorelin?

Tesamorelin is a 44-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that normally triggers GH secretion from the pituitary. It is engineered with a trans-3-hexenoic acid conjugation at its N-terminus, a structural modification that significantly increases stability against dipeptidyl peptidase IV (DPP-IV) cleavage compared to native GHRH, extending its functional activity without altering its receptor binding profile [1][2].

Marketed under the brand name Egrifta by Theratechnologies Inc., Tesamorelin holds the distinction of being the only FDA-approved GHRH analogue in clinical use. It received FDA approval in November 2010 for the reduction of excess abdominal fat (HIV-associated lipodystrophy) in HIV-infected adults receiving antiretroviral therapy — a condition in which subcutaneous fat redistributes to the visceral compartment, creating significant metabolic and cardiovascular risk [1].

This FDA approval is significant beyond the HIV context. It means Tesamorelin has undergone the most rigorous clinical testing of any GHRH-class peptide, with large-scale Phase III trials generating a well-characterised efficacy and safety dataset that researchers can draw on with considerably more confidence than the predominantly preclinical evidence base for most research peptides [1][6].

How it works: mechanism of action

Tesamorelin's mechanism is direct and well-understood: it binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs with high affinity, activating adenylate cyclase, raising intracellular cAMP, and stimulating the synthesis and pulsatile secretion of growth hormone [1][2].

Relationship to other GHRH analogues

The GHRH analogue class includes shorter fragments such as CJC-1295 No DAC (the 1-29 GHRH fragment). Tesamorelin is the full 44-amino-acid analogue of native GHRH with N-terminal modification. This longer sequence retains the full receptor-engagement architecture of endogenous GHRH. The key pharmacological difference from CJC-1295 No DAC is not mechanism but structural length and the N-terminal modification — tesamorelin does not carry the DAC (Drug Affinity Complex) that CJC-1295 with DAC uses to extend half-life; instead, it relies on the hexenoic acid modification for stability enhancement [1].

GH deficiency and visceral adiposity in HIV lipodystrophy

In HIV-infected individuals on antiretroviral therapy, chronic GH deficiency and altered GH pulsatility contribute directly to the visceral fat redistribution characteristic of lipodystrophy. Tesamorelin restores GH pulsatility → raises IGF-1 → promotes lipolysis in visceral adipocytes via hormone-sensitive lipase activation and adipocyte GH receptor signalling. The result is a selective reduction in visceral adipose tissue (VAT) without the broad metabolic disruption of exogenous GH [1][2].

Pulsatility preservation

Critically, tesamorelin — like all GHRH analogues — preserves the pulsatile character of GH secretion by working through the hypothalamic–pituitary axis rather than bypassing it. Somatostatin feedback, the normal GH pulse regulator, remains intact. This is the key mechanistic distinction from exogenous recombinant growth hormone (rhGH), which creates sustained supraphysiological GH and suppresses endogenous pulsatility [1][6].

Documented research and clinical benefits

Tesamorelin's clinical evidence base is substantially richer than that of most research peptides — it includes two large Phase III randomised controlled trials, secondary analyses, and separate investigator-initiated studies totalling thousands of patient-years of exposure.

Visceral fat reduction (primary approved indication)

The LIPO-010 and LIPO-011 Phase III trials, published by Falutz et al. (2010) in the New England Journal of Medicine, are the pivotal dataset. In the primary endpoint analysis, tesamorelin-treated HIV patients achieved a 15.2% reduction in trunk fat compared to 5.1% in the placebo group — a statistically significant and clinically meaningful difference [1]. CT-measured visceral adipose tissue (VAT) showed even more pronounced reductions. The effect was maintained over the 26-week trial period and reversed upon discontinuation, confirming the causal relationship.

Cognitive benefits: verbal memory and executive function

A secondary research dimension has emerged from the GH/IGF-1 axis's well-documented role in brain function. Baker et al. (2012) published a randomised controlled trial in Archives of Neurology demonstrating that tesamorelin administration in adults with mild cognitive impairment and healthy older adults produced significant improvements in verbal memory and executive function compared to placebo [3]. IGF-1 has established neuroprotective effects, and the GHRH-R is expressed in brain tissue — making tesamorelin an agent of genuine interest in cognitive ageing research.

Metabolic improvements and lipid profile

Beyond visceral fat reduction, the Phase III trials documented improvements in triglycerides and lipid profiles in HIV lipodystrophy patients — a population at elevated cardiovascular risk. Reductions in trunk fat translated into measurable improvements in cardiovascular risk markers, extending the clinical relevance beyond body composition [1][2].

NAFLD: emerging pilot evidence

Stanley et al. (2019) published a randomised, double-blind multicentre trial in The Lancet HIV examining tesamorelin's effects on non-alcoholic fatty liver disease (NAFLD) in HIV-infected adults. The results suggested benefit in liver fat reduction, adding NAFLD to the list of GH-axis-related conditions where tesamorelin research is active [4].

Lean mass maintenance

Alongside visceral fat reduction, tesamorelin trials consistently show maintenance or modest increase in lean body mass — consistent with GH's anabolic effects on skeletal muscle protein synthesis and the IGF-1 elevation it produces [1][2].

Dosing ranges in published literature

Tesamorelin is unique among research peptides in having an FDA-approved human dose — 2 mg SC once daily — which provides researchers with a rigorously validated reference point that most research peptides lack.

The consistency of 2 mg/day SC across multiple trial contexts is noteworthy — it reflects the Phase III programme's dose-selection work and suggests this is the effective human dose for GHRH-R engagement in the visceral fat and metabolic contexts studied. The cognitive research by Baker et al. (2012) also used doses in this range, further supporting the 2 mg SC once daily as the reference human dose [1][3].

Administration routes & reconstitution

Approved route and injection site

The FDA-approved protocol for Egrifta specifies subcutaneous injection into the abdomen once daily. Injection site rotation within the abdominal region is recommended — avoid using the same site repeatedly. The peri-umbilical area and areas with scar tissue, bruising, or inflammation should be avoided per the prescribing information [6].

Reconstitution

Egrifta is supplied as a lyophilised powder requiring reconstitution. The approved reconstitution protocol uses sterile water for injection (not bacteriostatic water, per the label). For research vials of tesamorelin, bacteriostatic water is typically used as standard for other research peptides — follow the specific instructions provided with research-grade material.

1. Allow the vial to reach room temperature before opening
2. Inject diluent slowly down the side of the vial — do not inject directly onto the powder
3. Gently swirl; do not shake or vortex
4. Inspect for particulates; discard if cloudy or discoloured
5. Use immediately after reconstitution (per FDA label); research-grade vials in BAC water: store at 2–8°C, use within 28 days

Side effects and safety data

Tesamorelin has the most robust clinical safety dataset of any GHRH-class research peptide, derived from controlled Phase III trials with hundreds of patients followed over 26–52 weeks. This dataset provides researchers with meaningful, quantified adverse event rates rather than theoretical risk assessments.

Common adverse effects (>5% in Phase III trials)

• Injection site reactions — erythema, pruritus, pain, induration; most common adverse effect; generally mild and manageable with site rotation [1]
• Arthralgia — joint pain; a class effect of GH elevation; typically dose-related [1]
• Myalgia — muscle aches; similarly a GH-class effect [1]
• Peripheral oedema — mild fluid retention secondary to GH's anti-natriuretic effects; generally resolves with continued use or dose adjustment [1]
• Hyperglycaemia — GH is counter-regulatory to insulin; blood glucose monitoring is recommended, particularly in subjects at risk for diabetes [1][6]

Less common adverse effects

• Carpal tunnel syndrome — a documented class effect of GH elevation; more likely with higher IGF-1 elevation; resolves with discontinuation [1][6]
• IGF-1 elevation above normal range — monitoring of IGF-1 levels is recommended; sustained supraphysiological IGF-1 is a theoretical long-term risk factor [6]

FDA contraindications (from prescribing information)

• Active malignancy — GH and IGF-1 promote cellular growth; tesamorelin is contraindicated in patients with active cancer [6]
• Pregnancy — contraindicated; effects on foetal development not established [6]
• Disruption of the hypothalamic–pituitary axis — pituitary tumour history, hypopituitarism, cranial irradiation — tesamorelin's mechanism requires an intact GH-secreting pituitary [6]

Interactions & contraindications

• Corticosteroids (antagonistic) — glucocorticoids blunt the GH response to GHRH stimulation by multiple mechanisms; chronic corticosteroid use reduces tesamorelin efficacy [1][6]
• Oral oestrogen (reduces IGF-1 response) — oral oestrogen significantly reduces hepatic IGF-1 production in response to GH stimulation; this interaction is specific to oral administration — transdermal oestrogen does not produce the same hepatic first-pass suppression of IGF-1 [6]
• Insulin and hypoglycaemics (antagonistic on glucose) — GH's counter-regulatory effect on insulin means tesamorelin use in diabetic research subjects or those on insulin requires blood glucose monitoring and potential adjustment of hypoglycaemic therapy [1][6]
• Antiretrovirals (no significant interaction) — in HIV trial populations, no significant pharmacokinetic interactions between tesamorelin and common antiretroviral regimens were documented — the HIV trial data specifically address this question [1][2]
• Somatostatin analogues (antagonistic) — directly oppose GH release; would substantially attenuate tesamorelin's effects

Storage & stability

Note: The FDA Egrifta label specifies use immediately after reconstitution with sterile water for injection. Research-grade vials reconstituted with bacteriostatic water may be stored refrigerated for up to 28 days — follow the specific instructions provided with research-grade material.

Frequently asked questions

Is Tesamorelin FDA-approved?

Yes — Tesamorelin (Egrifta, Theratechnologies Inc.) received FDA approval in November 2010 for the treatment of excess abdominal fat in HIV-infected adults on antiretroviral therapy who have HIV-associated lipodystrophy. This is the only approved indication. All other potential applications — including cognitive enhancement, NAFLD treatment, general body composition, and anti-ageing — are investigational and not covered by the FDA approval. The approval is, however, highly significant for researchers because it validates the safety and efficacy dataset through the most rigorous regulatory framework available [1][6].

How is Tesamorelin different from other GHRH analogues like CJC-1295?

Several key differences. Tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification; CJC-1295 No DAC is the shorter 1–29 fragment of GHRH with different N-terminal modifications. Tesamorelin has a short half-life (~26 minutes) that preserves pulsatility; CJC-1295 No DAC has a half-life of approximately 30 minutes (similar), while CJC-1295 with DAC extends to several days via albumin binding. Most importantly, tesamorelin is the only one with FDA approval and large-scale Phase III human data — CJC-1295 has no comparable clinical trial programme [1][6].

Can Tesamorelin help with visceral fat outside of HIV?

This is an active area of investigational research. The mechanism — restoring GH pulsatility → promoting visceral fat lipolysis — is not specific to HIV pathophysiology. The NAFLD study by Stanley et al. (2019) and the cognitive study by Baker et al. (2012) both involved populations outside the HIV approval. Pilot studies in HIV-negative subjects with metabolic syndrome and visceral obesity have been conducted, with encouraging preliminary data, but no FDA approval exists for these indications [1][4].

What are the cognitive benefits of Tesamorelin?

Baker et al. (2012) conducted a double-blind, placebo-controlled trial in adults with mild cognitive impairment (MCI) and healthy older adults, finding statistically significant improvements in verbal memory and executive function after 20 weeks of tesamorelin treatment (1–2 mg/day SC). The proposed mechanism involves GH/IGF-1 axis effects on hippocampal neurogenesis, synaptic plasticity, and prefrontal cortex function — IGF-1 has well-established neuroprotective properties. This is a particularly compelling area for future research given the absence of effective pharmacological interventions for MCI [3].

Is Tesamorelin available in India?

Tesamorelin (Egrifta) does not have drug approval in India and is not sold as a pharmaceutical here. It is available as a research compound for laboratory use and is not scheduled under the Drugs and Cosmetics Act 1940 as a restricted substance. As a frontier research compound, availability may be limited — contact PEPTIGRID via WhatsApp or check the catalog for current stock and pricing. See our introductory peptide guide for a fuller discussion of the Indian regulatory context.